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Background: Recently we reported the validation of the “Allergy-Control-SCORE© (ACS)” which assesses symptom
severity as well as medication use on three dimensions lung, nose and eyes. The aim of this study was to test the
validity of the score for eyes and nose.
Methods: One-hundred-twenty-one consenting subjects (age 19-65y), including 81 patients with allergic
rhino-conjunctivitis (RC) and 40 healthy controls, participated in the study. Patients rated daily nasal and eye
symptoms using a 4-point scale (none, mild, moderate, and severe) and their use of anti-symptomatic medication.
Validation criteria were pollen counts in the course of the study period. Discrimination capacity was analyzed by
comparing the rhino-conjunctivitis Allergy-Control-SCORE© (RC-ACS©) values of allergic patients and healthy
controls. Convergent reliability was assessed by correlating RC-ACS© values with the global severity of allergy, the
quality of life, and the allergy-related medical consultations. Retest reliability was assessed by the correlation of the
repeated measured RC-ACS© scores during each of two consecutive weeks.
Results: Convergent reliability analysis indicated a significant correlation between RC-Allergy-Control-SCORE© and
global severity of allergy (r= 0.691; p< 0.0001), quality of life (r= 0.757; p< 0.0001) and allergy-related medical
consultations (r= 0.329; p= 0.0019). RC-Allergy-Control-SCORE© showed a good retest reliability (r= 0.813; p< 0.001)
and discriminated extremely well between allergic patients and healthy controls (Median: 3.7 range: 0; 14.1 vs.
Median: 0 range: 0; 2.9; p < 0.001), with a sensitivity of 93.8% and a specificity of 92.5% at a score value of 0.786.
Conclusions: The RC-ACS© can be considered as valid and reliable to assess the severity of rhino-conjunctivitis
severity in clinical trials and observational studies.
Keywords: Symptom score, Medication score, Allergic disease, Rhino conjunctivitis, Symptom severityBackground
Recently we reported the validation of the “Allergy-
Control-SCORE© (ACS)” which includes three
categories: lung, nose and eyes [1]. Now we report the
validation of the score for eyes and nose, only. With this
new score we suggest an approach which covers a symp-
tom score, and a medication score, for eyes and nose
symptoms and use of symptomatic allergy medication to
a combined symptom-medication score (SMS), the
Rhino-Conjunctivitis Allergy-Control-Score (RC-ACS©).
Such a SMS is recommended to measure the primary
outcome of clinical trials on respiratory allergies [2],* Correspondence: dietrich.haefner@allergopharma.de
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reproduction in any medium, provided the orand the use is proposed by international regulatory
agencies, e.g. European Medicines Agency (EMA) [3].
With this validation we also report the outcome of the
validation of the Eye-Allergy-Control-Score (E-ACS©)
and the Nose-Allergy-Control-Score (N-ACS©). The
Allergy-Control-Score (ACS©). was used for several
years in different clinical trials [4-6]. In these studies
the score was used under the synonym, symptom medi-
cation score. The E-ACS© and the N-ACS© as well as
the RC-ACS© are parts of the Allergy-Control-SCORE©.
The RC-ACS© covers drugs used in clinical trials and
observational studies.
The concept of validation of the RC-ACS© is based on
measuring 1) convergent reliability and 2) retest reliabil-
ity in allergic patients as well as 3) discrimination cap-
acity in healthy controls and patients with respiratoryLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of the Rhino-conjunctivitis allergy
control score (RC-ACS)©, according to the GA2LEN
recommendations [8]
Acronym Rhino-Conjunctivitis Allergy Control Score
(RC-ACS©)
Author Kettner J., Narkus A., Häfner D.
Target To objectively monitor severity of allergic rhinitis
and allergic conjunctivitis




Existing translations German, Polish and others
Number of items 7 symptoms and 745 drugs
Tool dimensions see methods
Scaling of items Score points
Scoring of items 0-42 (global)





Performed trials Validation and use in different clinical trials
Copyright Allergopharma Joachim Ganzer KG
Contact information Häfner D. Medical Department Allergopharma J.
Ganzer KG, Hermann-Körner-Str. 52 21465 Reinbek
e-mail: dietrich.haefner@allergopharma.de
Table 3 Assessment of pollen counts according to the










Hazel 0 1-10 11-100 > 100
Alder 0 1-10 11-100 > 100
Birch 0 1-10 11-50 > 50
Grasses 0 1-5 6-30 > 30
Rye 0 1-2 3-6 > 6
Mugwort 0 1-2 3-6 > 6
Ragweed 0 1-5 6-10 > 10
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which included patients suffering from allergic rhinitis,
conjunctivitis or both and healthy controls. The conver-
gent reliability was assessed to determine the degree to
which the scores of an instrument show a relationship to
scores of similar instruments. For this purpose the cor-
relation to the following two instruments and twoTable 2 Example for the calculation of the medication













2 1 0 2 2
Levocabastine
NS*
2 1 0** 0 0
Mometasone
NS*
2 3 6 0 6
Loratadine 2 6 6*** 5 11
Sum 12 7 19
* SP= Score points; ED= Eye Drops; NS=Nasal Spray.
** It would be 2 SP for use of Levocabastine NS alone, but in combination
with the scores for Mometasone and Loratadine the maximum of 12 SP for
nose is reached.
*** It would be 7 SP for use of Loratadine alone, but in combination with the
Mometasone score the maximum of 12 SP for nose is reached.clinically important disease related health economic
measures was assessed: 1) Global Assessment of Severity
of Allergy by use of a Rating Scale; 2) Quality of Life
(RQLQ); 3) number of medical consultations due to the
allergy within the last 12 months; 4) the number of non-
productive days due to allergic rhino-conjunctivitis and/
or asthma within the last 12 months. Retest reliability is
the extent to which scores for patients who have not
changed are the same for repeated measurement over
time. The retest reliability was determined by correlating
the SMS values of the first week with the values of the
second week. The discrimination capacity reflects the
degree to which the scores of an instrument can dis-
criminate between different patient groups. Discrimin-
ation capacity was assessed by comparing the average
SMS values of the allergic patients (first week) and the
control group, respectively.
The validation of a Rhino-Conjunctivitis Allergy-
Control-Score (RC-ACS©) is an important and topical
issue in allergy clinical research. It is a relevant instru-
ment to assess rhino-conjunctivitis severity in clinical
trials and observational studies. With the validation a
formal aspect for reliable use of such an instrument is
fulfilled.
This Rhino-Conjunctivitis Allergy-Control-Score (RC-
ACS©) introduces the concept of “control of disease
(rhino-conjunctivitis)” as this will be the aim when using
any therapeutic intervention. The presented score bal-
ances symptoms and use of medication and it also con-
siders the influence of treatment on allergic symptoms.
Therefore, for calculating the combined symptom medi-
cation score, each medication will be assessed e.g.




Patients (age 19 to 65 years) were recruited from the out-
patient clinic department of “Dermatologikum Hamburg”,
Table 4 Socio-demographic data of the patient and control group
Patient group Control group
(n = 81) (n = 40)
M±SD Min Max Median M±SD Min Max Median
Age (years) 30.4 ± 9.7 19.0 65.0 28.0 35.5 ± 9.1 19.0 58.0 34.0
Height (cm) 172.3 ± 8.6 154.0 195.0 172.0 173.1 ± 9.6 156.0 191.0 173.5
Weight (kg) 68.0 ± 14.7 48.0 147.5 65.0 74.8 ± 18.9 45.0 130.0 71.0
Sex n % n %
Male 20 25.0 18 45.0
Female 61 75.0 22 55.0
Race n % n %
Caucasian 77 95.1 37 92.5
Hispanic 1 1.2 0 0.0
African 0 0.0 1 2.5
Asian 2 2.5 2 5.0
n: Sample size of subgroup M: Arithmetic mean. SD: Standard deviation. Min: Minimum. Max: Maximum.
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criteria were: 1) atopic sensitization (SPT positivity to at
least one of the following allergens: grass, rye, mugwort
pollen, house dust mites) (Allergopharma J. Ganzer KG,
Reinbek, Germany); 2) current clinical manifestations of
allergic rhino-conjunctivitis and/or asthma due to
exposure to one of the four allergens listed above; 3)
expected natural exposure to the relevant allergens during
the study period. Controls were non-atopic volunteers
with a negative history for IgE-mediated allergies. The fol-
lowing exclusion criteria were applied to patients and con-
trols: 1) current use of systemic or nasal corticosteroids,
inhaled corticosteroids (>400μg budesonide or >500μgTable 5 Medical history data of the patient group
Type I Allergy to n %
Grass pollen 67 83
Dust mites 57 73
Rye 53 65
Mugwort 26 33
Duration of Allergy (years) M± SD Min Max Median
Any allergy disorder 12.8 ± 8.7 1.0 50.0 10.0
Grass pollen 13.7 ± 9.2 1.0 50.0 11.0
Rye 15.1 ± 9.7 3.0 50.0 12.0
Mugwort 15.0 ± 8.6 3.0 37.0 14.0
Dust mites 11.8 ± 7.2 1.0 28.0 10.0
Allergic Illnesses n %
Allergic rhinitis 80 98.8
Allergic conjunctivitis 69 85.2
Allergic asthma 31 38.3
Atopic dermatitis 9 11.1
n: Number of subjects. M: Arithmetic mean. SD: Standard deviation.
Min: Minimum. Max: Maximum.beclomethasone dipropionate per day); 2) long-term
prophylactic use of anti-allergic medication with constant
dose; 3) current treatment with specific immunotherapy;
4) food allergy; 5) clinically-relevant rhinitis/rhino-con-
junctival or respiratory symptoms related to other uniden-
tified causes; 6) vasomotor, drug-induced or other kinds of
non-allergic rhinitis/rhino-conjunctivitis; 7) febrile infec-
tions or inflammation of the respiratory tract; 8) irrevers-
ible secondary alterations of the upper and lower airways
(e.g. emphysema, bronchiectasis etc.). The study protocol
was discussed with the local Ethics Committee before it
was commenced. The committee advised that formal ap-
proval was not required, because the study was observa-
tional and no changes in treatment were involved.
However, written informed consent was received from all
patients involved before they were included into the study.
Study design
The study was designed as prospective, observational
and controlled study. Patients and healthy controls com-
pleted a questionnaire on demographic and clinical para-
meters at recruitment. Scores of individual symptoms
and individual medications were documented daily dur-
ing the pollen season over a period of 2 weeks in
patients and 1 week in healthy controls, respectively. On
each day, patients and controls were also asked to
complete a self-administered questionnaire for a “Global
Assessment of Severity of Allergy”. This was performed
through a Visual Rating Scale (rating scale ranging from
1=no symptoms at all to 10 = very severe symptoms),
which is similar to the one described by Bousquet and
colleagues [7]. At the end of the first week, patients
completed a validated questionnaire to rate their quality
of life (RQLQ©) [8]. Participants started at different
times during the season, so that both study groups
Table 6 Severity of allergy in allergic patients vs. healthy controls
Allergic patients Healthy controls
Criterion n Mean± SD Median [range] n Mean± SD Median [range]
RC-ACS© (units) 80 4.3 ± 3.0 3.7 [0.0; 14.1] 40 0.2 ± 0.5 0.0 [0.0; 2.9]
E-ACS© (units) 80 1.2 ± 1.3 0.9 [0.0; 5.1] 40 0.0 ± 0.2 0.0 [0.0; 1.0]
N-ACS© (units) 80 3.0 ± 2.1 3.0 [0.0; 9.0] 40 0.1 ± 0.3 0.0 [0.0; 1.9]
Global Assessment of Severity of Allergy (Rating Scale 1-10) 80 3.6 ± 1.6 3.6 [1.0; 7.1] 40 1.1 ± 0.2 1.0 [1.0; 2.3]
Quality of Life (RQLQ total score) 79 1.9 ± 1.1 1.8 [0.2; 4.1] - n.a. n.a.
Medical Consultations due to allergy in the last 12 months 78 1.7 ± 2.5 1.0 [0.0; 12.0] - n.a. n.a.
Non-productive days due to allergy in the last 12 months 80 0.6 ± 2.5 0.0 [0.0; 15.0] - n.a. n.a.
n.a. = not applicable.
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pollen counts. In addition, patients were asked how
many days they were incapable of working due to their
allergic rhino-conjunctivitis and/or asthma within the
last 12 months (number of non-productive day).
RC-ACS©
Symptom score
The characteristics of the Rhino-Conjunctivitis Allergy-
Control-SCORE© as listed in Table 1 were elaborated
according to the GA(2)LEN taskforce Guidelines [9].
The symptom score is recorded using diaries in which
subjects documented daily the severity of various allergy
symptoms scaled according to the EMA guidelines [3]
on a scale ranging from 0 to 3: 0 = absent (no sign/
symptom evident); 1 =mild (sign/symptom clearly
present, but minimal awareness; easily tolerated);
2 =moderate (definite awareness of sign/symptom that
is bothersome, but tolerable); 3 = severe (sign/symptom
that is hard to tolerate; causes interference with activ-
ities of daily living and/or sleeping). For each day, the
sum of the values of the seven allergy symptoms is cal-
culated. These include ocular (itching, tear flow, red-
ness), and nasal (sneezing, itching, running, blockage)
symptoms.
Medication score
Patients also have to document the allergy medication
needed. All allergy medications for treating related
symptoms are scored for each patient and each available
day. Categories of medication taken into consideration
include nasal and ocular anti-histamines and glucocorti-
coids, nasal decongestants, nasal cromoglycate acid and
salts, systemic antihistamines, glucocorticoids and their
combinations, leukotriene receptor antagonists. Drugs
not foreseen by international Guidelines for treating
allergic rhino-conjunctivitis are not included (e.g. anti-
IgE). The total number of “score points” (SP) for symp-
toms on one day is 21 (i.e. each of the 7 symptoms
scored with a maximum of 3). The maximum SP thatcan be achieved by intake of medication is also set to 21
SP, subdivided into the two sub-scores for nose (max. 12
SP) and eyes (max. 9 SP). Each drug is scored consider-
ing pharmacological action (according to the corre-
sponding ATC code), expected impact on symptoms,
route of administration, the dose taken and duration of
effect. Each medication score is balanced for the respect-
ive weight on symptoms and within the maximum score
of each organ system. Thus scoring of medication can-
not yield a higher value than symptoms at the respective
organ. An example for the scoring of medications is
given in Table 2. In this example a patient had a com-
bined intake of glucocorticoid-containing nasal spray,
antihistaminic eye drops and nasal spray as well as sys-
temic antihistamine. The most potent drugs are scored
first; in this case the local glucocorticoids are scored. In
case the maximum score of the corresponding subscore
is not reached, the score for topical or systemic antihis-
tamines is added until the maximum score points are
reached (nose: 12 SP eyes: 9 SP). In case both systemic
antihistamines and local antihistamines are given, the
systemic antihistamine e.g. loratadine is scored first. The
sum of SP of topical, systemic antihistamines and
combination-drugs containing antihistamine cannot ex-
ceed 7 SP for the subscore nose and 5 SP for the sub-
score eyes, respectively.
Symptom-medication-score
The RC-ACS© is obtained by adding the daily medication
score to the daily symptom score leading to a range of 0 to
42 SP. Similarly, the N-ACS© as well as the E-ACS© is
calculated. The daily E-ACS© and N-ACS© range from 0 to
18 SP and 0 to 24 SP, respectively.
Pollen counts
Pollen counts (grasses, rye and mugwort) were derived
from the European pollen information database
(European Aeroallergen Network, Vienna, Austria) be-
tween 21 June and 17 August 2008 for the pollen traps
in Lübeck and Reinbek. Pollen exposition was assessed
Figure 1 Discrimination capacity of the SMS. Frequency
distribution of the SMS among 81 allergic patients (A) and 40
healthy control subjects (B). Panel (C) shows a ROC curve of the
discrimination power of patients vs. controls; the area under the
curve is 0.9755; the best discrimination point is 0.786, corresponding
to a sensitivity of 93.8% and a specificity of 92.5%.
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“Strong”) according to the definition of the German
Meteorological Service) for each week of assessment
(Table 3).Statistics
Descriptive analysis
Background and demographic characteristics of subjects
are summarized for both groups. Continuous variables
are displayed by sample size, mean, median, standard de-
viation and range. Discrete variables are shown with fre-
quencies and percentages. Missing SMS values were
replaced by linear interpolation if at most 25% of the
values were missing. Regarding all other parameters, the
last-observation-carried-forward (LOCF) method was
applied. Data management and statistical analysis were
performed using the statistical analysis program SPSS
Version 15.0 (SPSS Inc., Chicago, USA).
Validation of the RC-ACS©
The dataset was analyzed to measure the convergent re-
liability, discrimination capacity, and retest reliability, as
follows.
Convergent reliability Convergent reliability is the
degree to which the scores of an instrument show a rela-
tionship to scores of similar instruments. The conver-
gent reliability of the RC-ACS© and the total N-ACS© as
well as the total E-ACS© was tested by correlating the
average SMS value of week 1 with the following four
parameters: 1) Global Assessment of Severity of Allergy
(Rating Scale 1–10); 2) Quality of Life (RQLQ); 3) num-
ber of medical consultations due to the allergy within
the last 12 months; 4) the number of non-productive
days due to allergic rhino-conjunctivitis and/or asthma
within the last 12 months. Spearman’s rank correlations
were calculated for each of the criteria 1 to 4. A signifi-
cant positive correlation (p < 0.05, two-tailed) was con-
sidered as evidence for convergent validity. This
corresponds in this study to a medium effect size
(r ≥ 0.30) which can be regarded as a considerable
correlation [10].
Discrimination capacity The discrimination capacity is
the degree to which the scores of an instrument can dis-
criminate between different patient groups.
Discrimination capacity of the RC-ACS© and the total
N-ACS© as well as the total E-ACS© was assessed by
comparing the average SMS values of the allergic
patients (first week) and the control group, respectively.
Discrimination capacity was assumed to be good if the
SMS value in the allergy group was significantly higher
(p < 0.05, two-tailed) than the SMS value of the control
group. Significance testing was performed with the
Wilcoxon Rank Sum test. Sensitivity and specificity were
analyzed by a ROC-curve.
Retest reliability Retest Reliability is the extent to
which scores for patients who have not changed are the
Table 7 Correlation of the RC-ACS©, E-ACS©and N-ACS©with further assessment tools for the severity of allergy
RC-ACS© E-ACS© N-ACS©
Criterion r p r p r p
Global Assessment of Severity of Allergy (Rating Scale 1–10) 0.6910 <0.0001 0.4873 <0.0001 0.6867 <0.0001
Quality of Life (RQLQ total score) 0.7573 <0.0001 0.6547 <0.0001 0.7043 <0.0001
Medical Consultations due to allergy in the last 12 months 0.3288 0.0019 0.2613 0.0192 0.2939 0.0008
Non-productive days due to allergy in the last 12 months 0.0253 0.8239 −0.0773 0.4954 0.0681 0.5482
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reliability was determined for the patient group only, by
correlating the SMS values of the first week with the
values of the second week. Comparisons were conducted
using Spearman’s rank correlations.
Results
Socio-demographic and clinical data
A total of 122 adults (82 allergic patients and 40 healthy
controls) were screened for inclusion into the study. Of
the 82 patients, 81 fulfilled the in/exclusion criteria and
were included in the study and 80 completed the entire
study. All 40 control subjects completed the study. The
socio-demographic data of both groups are shown in
Table 4 and the data on medical history of allergic dis-
eases are given in Table 5 for the patient group.
Severity of symptoms in allergic patients vs. healthy
controls
The severity of symptoms in allergic patients vs. healthy
controls is shown in Table 6. Clearly, patients had higher
values than healthy controls. Controls had values close
to the lowest possible values. Since healthy controls were
non-allergic based on their medical history, symptom
rating of the control patients is due to other factors than
allergic symptoms.
Discrimination capacity of the RC-ACS©
The patient group showed a significantly higher mean
RC-ACS© in comparison to the control group (Median:
3.7 range: 0; 14.1 vs. Median: 0 range: 0; 2.9; p < 0.001,
two-sided Wilcoxon Rank Sum test) (Figure 1A and B).
The same was seen also for the E-ACS© (patient group:
Median: 0.9; range: 0; 5.1 vs. control group: Median: 0;
range: 0; 1.0; p < 0.001, two-sided Wilcoxon Rank Sum
test) and the N-ACS© (patient group: Median: 3.0; range:
0; 9.0 vs. control group: Median: 0; range: 0; 1.9;Table 8 Re-test reliability of RC-ACS©, E-ACS©and N-ACS©
Week 1 Week 2
Criterion Mean± SD Mean± SD r p
RC-ACS© (units) 4.3 ± 3.0 4.0 ± 3.1 0.8134 <0.0001
E-ACS©(units) 1.2 ± 1.3 1.2 ± 1.3 0.7716 <0.0001
N-ACS©(units) 3.0 ± 2.1 2.9 ± 2.2 0.7990 <0.0001p < 0.001, two-sided Wilcoxon Rank Sum test). Thus,
RC-ACS©, E-ACS© and N-ACS© separated excellently
between patient and control group. The best possible
SMS-cut-off-value with a sensitivity of 93.8% and a spe-
cificity of 92.5% was 0.786 (Figure 1C). In other words,
93.8% of the allergic patients had an RC-ACS© of 0.786
or higher and thus could be assigned correctly to the al-
lergy group. The same analysis has been repeated separ-
ately for E-ACS© and N -ACS© and provided similar
results (data not shown).
Convergent reliability of the RC-ACS©
A statistically significant (p < 0.0001, two-tailed) positive
correlation was observed between the RC-ACS© and the
Global Assessment of the Severity of Allergy, the Quality
of Life, and the number of medical consultations due to
the allergic disease, but not with the number of non-
productive days due to allergic rhino-conjunctivitis and/
or asthma within the last 12 months (Table 7). However,
only seven patients (8.75%) had lost at least one pro-
ductive day due to allergy.
Re-test reproducibility of RC-ACS© over time
In the patient group, the average RC-ACS© values of
week 1 and week 2 were almost identical (week
1 = 4.3 ± 3.0; week 2 = 4.0 ± 3.1 (Table 8)). The RC-ACS©
values of the first and second week correlated signifi-
cantly (r = 0.8134, p < 0.0001, two-tailed). The reproduci-
bility of the E-ACS© and N-ACS© (Table 8) was
comparable (E-ACS©, week 1: 1.2 ± 1.3 vs. week 2:
1.2 ± 1.3; r = 0.7716, p < 0.0001; N-ACS©, week 1:
3.0 ± 2.1 vs. week 2: 2.9 ± 2.2; r = 0.7990, p < 0.0001).
Pollen counts
The pollen counts of Poaceae in the two aerobiology sta-
tions were monitored during an eight-week period




This study evaluated the validity of the RC-ACS©, a
symptom-medication score which assesses severity of
nasal and ocular allergy by considering symptoms and
intake of anti-allergic medication. RC-ACS© is reliable,
Figure 2 Pollen exposure during the study period. Pollen counts in two sites representative for this region during the whole study period.
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liability analysis showed highly significant correlations
with Global Assessment of Allergy Severity, Quality of
Life, and the number of medical consultations due to al-
lergy within the past year; 2) it discriminated signifi-
cantly between patient and control groups (p < 0.001); 3)
it showed good retest reliability; 4) it had an excellent
sensitivity (93.8%) and specificity of (92.5%) in discrimin-
ating between patients and healthy controls. Thus, the
RC-ACS© is considered as a reliable and valid instru-
ment evaluating severity of symptoms of nasal and ocu-
lar allergies. The same holds also true for the elements
of the RC-ACS© i.e. the N-ACS© and the E-ACS©.
Peculiarities of the RC-ACS©
RC-ACS© is based on scoring nose and ocular symptoms
and use of symptomatic medications. It includes a full
list of relevant drugs, i.e. without any limitation in drugs.
Each score can be used separately or combined. Thus,
RC-ACS© can be used in daily practice and real-life
situations. Of note is the fact that, as with the ACS©, the
RC-ACS© balances impact of symptoms and drugs. Al-
though with this RC-ACS© a recommendation of the
EMA guideline [3] can be met, it has to be considered
that rhino-conjunctivitis can precede asthma [11] and
often patients have both rhino-conjunctivitis and asthma
[12]. Thus it is important to collect also lung symptomsin order to make assessments on development of
asthma.
The combination of symptom and medication score
The RC-ACS© and the subscores E-ACS© and N-ACS©
combine scoring of symptoms and medication by sum-
ming up both. For the symptom score and medication
score separately, the retest reliability and discrimination
power were excellent (data not shown). In contrast to
the combined use of “Average Rhinoconjunctivitis Total
Symptom Score” (ARTSS) and “Average Rescue Medica-
tion Score (ARMS)” [13] which has been specifically
designed considering WAO recommendations [2], the
RC-ACS© weights rescue medication, and balances res-
cue medication and symptoms. The advantage of the
RC-ACS© is the individual scoring of each medication
according to their ACT class, based on efficacy, mode of
action, mode of administration, and duration of action.
Other instruments
A visual analog scale as used by Bousquet and colleagues
[7] seems to be an easy to use instrument to assess effi-
cacy of e.g. specific immunotherapy. However, nowadays
a visual analog scale as used by Bousquet and colleagues
[7] will no longer be accepted by health authorities to
achieve approval for new medications especially if used
for specific immunotherapy because the EMA guideline
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both, symptom severity as well as the intake of rescue
medication”. The present article does not claim to have
a comprehensive discussion of all available instruments.
For this purpose the authors would like to refer to a re-
cently published review on such instruments by Pfaar
and colleagues [14].
Cross-cultural validation
RC-ACS© is available in German, English, Polish and
other languages. Translation to other languages may be
possible. The Medication Score can be used worldwide
because use of ATC codes guarantees that even country-
specific therapies can be coded.
Conclusions
This study shows that the RC-ACS© is a valid and reli-
able diagnostic tool, for assessing, and monitoring al-
lergy severity. It considers both, symptoms and allergy
medication. The structure is robust enough for using it
in clinical trials and daily clinical practice. Therefore,
with this validated RC-ACS© there is a tool available
which focuses only on rhino conjunctivitis. However, it
has to be noted that the full picture of an allergic patient
cannot be assessed without collecting data on lung func-
tion. With this paper we want to take the opportunity
for opening a discussion on validation of such instru-
ments and how it may be performed in the future and
how it can be improved.
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